Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Montelukast Sodium Market

Montelukast Sodium Market Trends

Report ID: GMI9309
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Montelukast Sodium Market Trends

Advancements in drug delivery have revolutionized the landscape of pharmaceuticals, offering novel opportunities to enhance the efficacy, safety, and patient experience of various medications. This is particularly pertinent in the realm of respiratory medicine, for conditions such as asthma and allergic rhinitis present significant therapeutic challenges. Among the key medications used in managing these respiratory disorders is montelukast sodium, a leukotriene receptor antagonist known for its anti-inflammatory properties.

Innovative drug delivery technologies can improve the absorption and bioavailability of montelukast sodium, ensuring that a higher percentage of the medication reaches the target site in the body, leading to improved therapeutic outcomes.
Novel drug delivery systems such as extended-release formulations or convenient dosage forms can enhance patient convenience and compliance by reducing the frequency of dosing or eliminating the need for water for administration.
Similarly, advanced drug delivery technologies can help to mitigate the potential side effects associated with montelukast sodium by optimizing drug release kinetics, reducing dose variability, and minimizing exposure to non-target tissues. Thereby escalating the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Montelukast sodium market size was USD 670.7 million in 2023 and is expected to register 11.4% CAGR from 2024-2032 owing to the increasing prevalence of respiratory diseases includes asthma, allergic rhinitis worldwide.

Montelukast sodium industry from the montelukast sodium amorphous segment reached USD 387.6 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to having a higher solubility than their crystalline counterparts.

U.S. montelukast sodium industry is expected to register 11.1% CAGR from 2024-2032 due to the presence of highly developed healthcare infrastructure with advanced medical facilities and a robust pharmaceutical industry in the region.

Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd, Merck & Co., Inc., Morepen Laboratories Limited, Mylan N.V., Sandoz AG, Sanofi, Sun Pharma Industries Limited., and Teva Pharmaceutical Industries Limited, are some of the major montelukast sodium companies worldwide.